{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T17:57:08Z","timestamp":1782755828830,"version":"3.54.5"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,5]]},"DOI":"10.7759\/cureus.91679","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T18:37:23Z","timestamp":1757097443000},"source":"Crossref","is-referenced-by-count":3,"title":["Unmasking Semaglutide-Induced Gastroparesis: The Dangers of Rapid Dose Escalation in a Diabetic Patient"],"prefix":"10.7759","author":[{"given":"Rohan","family":"Singhal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dheerja","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Wortman II","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha","family":"Lall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.09.055","article-title":"American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis","volume":"127","author":"Parkman HP","year":"2004","unstructured":"Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004, 127:1592-622. 10.1053\/j.gastro.2004.09.055","journal-title":"Gastroenterology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2011.116","article-title":"Gastroparesis: pathogenesis, diagnosis and management","volume":"8","author":"Hasler WL","year":"2011","unstructured":"Hasler WL. Gastroparesis: pathogenesis, diagnosis and management. Nat Rev Gastroenterol Hepatol. 2011, 8:438-53. 10.1038\/nrgastro.2011.116","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0b013e328358d619","article-title":"Gastroparesis","volume":"28","author":"Hasler WL","year":"2012","unstructured":"Hasler WL. Gastroparesis. Curr Opin Gastroenterol. 2012, 28:621-8. 10.1097\/MOG.0b013e328358d619","journal-title":"Curr Opin Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng Z","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024, 9:234. 10.1038\/s41392-024-01931-z","journal-title":"Signal Transduct Target Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker DJ","year":"2024","unstructured":"Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024, 47:1873-88. 10.2337\/dci24-0003","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker DJ","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018, 27:740-56. 10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos TD","year":"2014","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014, 11:202-30. 10.1900\/RDS.2014.11.202","journal-title":"Rev Diabet Stud"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi M","year":"2023","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023, 330:1795-7. 10.1001\/jama.2023.19574","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.123.266800","article-title":"Glucagonlike peptide-1 receptor agonists: the good, the bad, and the ugly\u2014benefits for glucose control and weight loss with side effects of delaying gastric emptying","volume":"52","author":"Parkman HP","year":"2024","unstructured":"Parkman HP, Rim DS, Anolik JR, Dadparvar S, Maurer AH. Glucagonlike peptide-1 receptor agonists: the good, the bad, and the ugly\u2014benefits for glucose control and weight loss with side effects of delaying gastric emptying. J Nucl Med Technol. 2024, 52:3-7. 10.2967\/jnmt.123.266800","journal-title":"J Nucl Med Technol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2024-001704","article-title":"Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy - a retrospective cohort study","volume":"12","author":"Aneke-Nash C","year":"2025","unstructured":"Aneke-Nash C, Hung KS, Wall-Wieler E, Zheng F, Sharaiha RZ. Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy - a retrospective cohort study. BMJ Open Gastroenterol. 2025, 12:e001704. 10.1136\/bmjgast-2024-001704","journal-title":"BMJ Open Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.52564","article-title":"Tendency of semaglutide to induce gastroparesis: a case report","volume":"16","author":"Chaudhry A","year":"2024","unstructured":"Chaudhry A, Gabriel B, Noor J, Jawad S, Challa SR. Tendency of semaglutide to induce gastroparesis: a case report. Cureus. 2024, 16:e52564. 10.7759\/cureus.52564","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/23247096211051919","article-title":"Medication-induced gastroparesis: a case report","volume":"9","author":"Kalas MA","year":"2021","unstructured":"Kalas MA, Galura GM, McCallum RW. Medication-induced gastroparesis: a case report. J Investig Med High Impact Case Rep. 2021, 9:10.1177\/23247096211051919","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000966968.44182.37","article-title":"I miss eating: medication-induced gastroparesis from semaglutide","volume":"118","author":"Gomez P","year":"2023","unstructured":"Gomez P, Gutierrez VA, Narang N, Goldberg A. I miss eating: medication-induced gastroparesis from semaglutide. Am J Gastroenterol. 2023, 118:S2726. 10.14309\/01.ajg.0000966968.44182.37","journal-title":"Am J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1586\/eem.10.41","article-title":"Metoclopramide in the treatment of diabetic gastroparesis","volume":"5","author":"Lee A","year":"2010","unstructured":"Lee A, Kuo B. Metoclopramide in the treatment of diabetic gastroparesis. Expert Rev Endocrinol Metab. 2010, 5:653-62. 10.1586\/eem.10.41","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/gidisord5030026","article-title":"Metoclopramide in gastroparesis: its mechanism of action and safety profile","volume":"5","author":"Kalas MA","year":"2023","unstructured":"Kalas MA, Trivedi B, Kalas M, Chavez LO, McCallum RW. Metoclopramide in gastroparesis: its mechanism of action and safety profile. Gastrointest Disord. 2023, 5:317-28. 10.3390\/gidisord5030026","journal-title":"Gastrointest Disord"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez JJ","year":"2022","unstructured":"Gorgojo-Mart\u00ednez JJ, Mezquita-Raya P, Carretero-G\u00f3mez J, et al.. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022, 12:145. 10.3390\/jcm12010145","journal-title":"J Clin Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/386367-unmasking-semaglutide-induced-gastroparesis-the-dangers-of-rapid-dose-escalation-in-a-diabetic-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T18:37:23Z","timestamp":1757097443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/386367-unmasking-semaglutide-induced-gastroparesis-the-dangers-of-rapid-dose-escalation-in-a-diabetic-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.91679","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,5]]}}}